Cost-Effectiveness Analysis of Chatbot-Supported Remote Patient Monitoring for Anticoagulation Management: Health...

Digital health technologies (DHTs) are increasingly integrated into clinical practice, yet economic evaluations remain scarce, particularly in the early development stages. Within the NICE (National Institute for Health and Care Excellence) Evidence Standards Framework, Tier C DHTs comprise technologies with direct clinical implications and measurable health outcomes, for which robust economic evidence is essential. Early-stage assessments are particularly important to inform subsequent development, refinement, and adoption decisions across the digital health lifecycle.

This study aims to explore the feasibility of integrating a full trial-based economic evaluation within an early-stage pilot comparing a chatbot-supported remote patient monitoring (RPM) solution for anticoagulation management with the standard of care (SOC).

A cost-effectiveness analysis was performed alongside a pilot crossover trial among adult cardiac surgery patients receiving vitamin K antagonists. Participants were allocated to two 6-month sequences (SOC→RPM or RPM→SOC). The intervention consisted of a rule-based chatbot integrated with home-based international normalized ratio self-testing using portable coagulometers to support communication and therapy management. Effectiveness was measured as time in therapeutic range (TTR), and costs were estimated from the Portuguese National Health Service and a limited societal perspective over a 1-year horizon. The analysis 1 applied a within-patient cost-effectiveness approach to estimate incremental costs, incremental TTR, and incremental cost-effectiveness ratios. Uncertainty was explored through nonparametric bootstrapping (5000 replications) and deterministic sensitivity analyses. Complementary comparisons examined differences between sequences (analysis 2), between periods (analysis 3), and within each sequence (analysis 4).

A total of 19 patients were included in the analyses. In analysis 1, RPM improved anticoagulation control, with a mean within-patient increase of 10.43 percentage points in time in TTR. The mean incremental costs were €198.61 (€1=US $1.08) from the Serviço Nacional de Saúde perspective and €270.05 from the limited societal perspective. The corresponding incremental cost-effectiveness ratios were €19.03 and €25.88 per additional percentage point of TTR gained. Sensitivity analyses produced consistent estimates across parameter variations. Complementary analyses (2-4) suggested that RPM tended to be more cost-effective when implemented after the initial 6-month postoperative period.

This proof-of-concept study demonstrates that a full trial-based economic evaluation can feasibly be embedded within an early-stage Tier C DHT. The intervention showed improved anticoagulation control alongside higher costs, providing initial insights into its cost-effectiveness profile. Positioned within the digital health evidence continuum, such assessments can function as a learning stage within the lifecycle. To address the persistent adoption-evidence gap, tier- and stage-aligned frameworks are needed to guide the economic evaluation of DHTs. This study contributes to that goal by providing a set of recommendations specifically for Tier C DHTs.